Firolyptol and Firolyptol with Kreosote


Title
Firolyptol and Firolyptol with Kreosote
Description
Tan and green ink blotter advertising Firolyptol and Firolyptol with Kreosote. It is stated that this is "the most recent, most valuable addition to therapeutics in the treatment of tuberculosis and struma extant." A drawing of a fir tree is in the upper left corner of the ink blotter. A word has been written below the tree that is not readable. The word "Henry" has been written in the upper right corner. The products are prepared by The Tilden Company, New Lebanon, N.Y. and St. Louis, Mo. This ink blotter shows heavy use on the reverse side.
Date
1900-1930
Original Format
trade cards
Extent
23cm x 10cm
Local Identifier
LL02.12.02.01.04
Creator(s)
Subject(s)
Spatial
Location of Original
Laupus Library History Collections
Rights
This item has been made available for use in research, teaching, and private study. Researchers are responsible for using these materials in accordance with Title 17 of the United States Code and any other applicable statutes. If you are the creator or copyright holder of this item and would like it removed, please contact us at als_digitalcollections@ecu.edu.
http://rightsstatements.org/vocab/InC-EDU/1.0/
Permalink
https://digital.lib.ecu.edu/22150
Preferred Citation
Cite this item
Content Notice

Public access is provided to these resources to preserve the historical record. The content represents the opinions and actions of their creators and the culture in which they were produced. Therefore, some materials may contain language and imagery that is outdated, offensive and/or harmful. The content does not reflect the opinions, values, or beliefs of ECU Libraries.

Contact Digital Collections

If you know something about this item or would like to request additional information, click here.


Comment on This Item

Complete the fields below to post a public comment about the material featured on this page. The email address you submit will not be displayed and would only be used to contact you with additional questions or comments.


*
*
*
Comment Policy